{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:33:51Z","timestamp":1788406431171,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T00:00:00Z","timestamp":1447718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The\n            <jats:italic>in vitro<\/jats:italic>\n            activity of isavuconazole against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mucorales<\/jats:named-content>\n            isolates measured by EUCAST E.Def 9.2 and CLSI M38-A2 methodologies was investigated in comparison with those of amphotericin B, posaconazole, and voriconazole. Seventy-two isolates were included: 12 of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Lichtheimia corymbifera<\/jats:named-content>\n            , 5 of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Lichtheimia ramosa<\/jats:named-content>\n            , 5 of group I and 9 of group II of\n            <jats:italic>Mucor circinelloides<\/jats:italic>\n            , 9 of\n            <jats:italic>Rhizomucor pusillus<\/jats:italic>\n            , 26 of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Rhizopus microsporus<\/jats:named-content>\n            , and 6 of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Rhizopus oryzae<\/jats:named-content>\n            . Species identification was confirmed by internal transcribed spacer (ITS) sequencing. EUCAST MICs were read on day 1 (EUCAST-d1) and day 2 (EUCAST-d2), and CLSI MICs were read on day 2 (CLSI-d2). Isavuconazole MIC\n            <jats:sub>50<\/jats:sub>\n            s (range) (mg\/liter) by EUCAST-d1, CLSI-d2, and EUCAST-d2 were 1 (0.125 to 16), 1 (0.125 to 2), and 4 (0.5 to &gt;16), respectively, across all isolates. The similar values for comparator drugs were as follows: posaconazole, 0.25 (\u22640.03 to &gt;16), 0.25 (0.06 to &gt;16), and 1 (0.06 to &gt;16); amphotericin, 0.06 (\u22640.03 to 0.5), 0.06 (\u22640.03 to 0.25), and 0.125 (\u22640.03 to 1); voriconazole, 16 (2 to &gt;16), 8 (1 to &gt;16), and &gt;16 (8 to &gt;16), respectively. Isavuconazole activity varied by species:\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Lichtheimia corymbifera<\/jats:named-content>\n            , 1 (0.5 to 2), 1 (1 to 2), and 2 (1 to 4);\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Lichtheimia ramosa<\/jats:named-content>\n            , 0.25 (0.125 to 0.5), 1 (0.5 to 2), and 2 (0.5 to 4);\n            <jats:italic>Rhizomucor pusillus<\/jats:italic>\n            , 0.5 (0.5 to 1), 1 (0.125 to 1), and 2 (1 to 2);\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Rhizopus microsporus<\/jats:named-content>\n            , 1 (0.5 to 4), 0.5 (0.125 to 1), and 4 (1 to 8); and\n            <jats:italic>Rhizopus oryzae<\/jats:italic>\n            , 1 (0.5 to 4), 1 (0.125 to 2), and 4 (0.5 to 8), respectively, were more susceptible than\n            <jats:italic>Mucor circinelloides<\/jats:italic>\n            : group I, 8 (4 to 8), 4 (2 to 4), and 16 (2 to 16), respectively, and group II, 8 (1 to 16), 8 (1 to 8), and 16 (4 to &gt;16), respectively. This was also observed for posaconazole. The essential agreement was best between EUCAST-d1 and CLSI-d2 (75% to 83%). Isavuconazole displayed\n            <jats:italic>in vitro<\/jats:italic>\n            activity against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mucorales<\/jats:named-content>\n            isolates with the exception of\n            <jats:italic>Mucor circinelloides<\/jats:italic>\n            . The MICs were in general 1 to 3 steps higher than those for posaconazole. However, in the clinical setting this may be compensated for by the higher exposure at standard dosing.\n          <\/jats:p>","DOI":"10.1128\/aac.01919-15","type":"journal-article","created":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T02:28:33Z","timestamp":1444098513000},"page":"7735-7742","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":99,"title":["<i>In Vitro<\/i>\n            Activity of Isavuconazole and Comparators against Clinical Isolates of the\n            <i>Mucorales<\/i>\n            Order"],"prefix":"10.1128","volume":"59","author":[{"given":"Maiken Cavling","family":"Arendrup","sequence":"first","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Hare","family":"Jensen","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ571"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12371"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065110"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu052.532"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","unstructured":"Vehreschild MJGT Vehreschild JJ Marty FM Perfect J Ostrosky-Zeichner L Rahav G Zeiher B Lee M Maher R Lovell C Engelhardt M Cornely OA. 2014. Primary treatment of invasive mucormycosis (IM) with isavuconazole (VITAL Study) or amphotericin formulations (FungiScope): case-matched analysis poster 1152. 56th ASH Annu Meet.","DOI":"10.1182\/blood.V124.21.1151.1151"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01530-08"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-010-9324-3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04055-14"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-07"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1117018109"},{"key":"e_1_3_3_12_2","volume-title":"EUCAST definitive document E.Def 9.2 method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds","author":"Arendrup MC","year":"2014","unstructured":"Arendrup MC, Hope W, Howard SJ. 2014. EUCAST definitive document E.Def 9.2 method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST, V\u00e4xj\u00f6, Sweden."},{"key":"e_1_3_3_13_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard","author":"CLSI","year":"2008","unstructured":"CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. CLSI, Wayne, PA.","edition":"2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01111-13"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03880.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.01.001"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03890.x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12148"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00686-11"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00536-10"},{"key":"e_1_3_3_21_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"Desai A","year":"2014","unstructured":"Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R. 2014. Isavuconazole (ISA) population pharmacokinetic modeling from phase 1 and phase 3 clinical trials and target attainment analysis, abstr A-697. Abstr 54th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.658-666.2006"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03050-14"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02686-13"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00702-11"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02808-13"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt229"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000163"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03644.x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00636-13"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0552-6"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02301-13"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.3.272"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01919-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01919-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:02:30Z","timestamp":1645484550000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01919-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1128\/AAC.01919-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01919-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"2015-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}